Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom by Kwame Owusu-Edusei, Cody Palmer, Olga Ovcinnikova, Giampiero Favato, Vincent Daniels

“…**Background:** The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. …”
Get full text

ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV by Delia Pinto-Santini, Emilia M. Jalil, Giovana Teixeira Fernandes, Genevieve Hilaire, Lenka Kolevic, Robinson Cabello, Beatriz Grinsztejn, William Pape, Marie Marcelle Deschamps, Margaret G. House, Emma Brofsky, Vikrant V. Sahasrabuddhe, Sayan Dasgupta, Siavash Pasalar, Margaret M. Madeleine, Joseph Carter, Priya R. Prabhu, Denise Galloway, Ann Duerr

“…Methods The OPTIMO study will compare immune responses to HPV vaccination in CLWH by measuring antibody and memory B cell (Bmem) responses after 1, 2, or 3 doses of the 9-valent HPV (9vHPV) vaccine, Gardasil-9. A comparison group of children without HIV will receive one dose of the vaccine. …”
Get full text